Categories: News

Financière de Tubize – 2022 half-year financial report

Press release
30 July 2022
Embargo till 08:00h CET

FINANCIERE DE TUBIZE SA

Allée de la Recherche 60, 1070 Brussels

Contact: Eric Nys, day-to-day management, eric.nys@financiere-tubize.be

2022 half-year financial report

Regulated information
30 July 2022

The board of directors of Financière de Tubize has issued the 2022 half-year financial report. This report is available on the website www.financiere-tubize.be

  • Profit for the period in accordance with Belgian accounting standards: € 87,3 million at 30 June 2022, compared to € 85,0 million at 30 June 2021 (increase of 2,7%),
  • Profit for the period in accordance with International Financial Reporting Standards (IFRS): € 144,5 million at 30 June 2022, compared to € 204,8 million at 30 June 2021 (decrease of 29,4%),
  • Dividend received from UCB: € 89,0 million (€ 1,30 per share, an increase of 2,4% compared to the previous year),
  • 2021 Dividend paid to Financière de Tubize’s shareholders in 2022 of € 33,4 million (€ 0,75 per share, an increase of  10,3% compared to the previous year),      
  • Increase by € 25,0 million of outstanding bank borrowings from € 20,0 million at 31 December 2021 to € 45,0 million at 30 June 2022,
  • Acquisition of 1.053.840 UCB shares, for a total amount of € 94,5 million, at an average price of € 89.64, increasing the holding of the Company in UCB from 35,16% at 31 December 2021 to 35,70% at 30 June 2022.

Staff

Recent Posts

Understanding When to Use Fillers or Neurotoxins According to Dr. Ran Rubinstein

Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…

2 hours ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…

2 hours ago

Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…

2 hours ago

ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…

2 hours ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Company expects up to six-month review period per FDA guidelines  New longer-term clinical data demonstrating…

2 hours ago